- The treatment of patients with locally advanced non-small cell lung cancer (stage III) has changed significantly in the past few years. - Patients with a non-resectable stage IIIA/B tumour are given combined treatment consisting of chemotherapy and radiotherapy. These can be administered sequentially or concurrently. - It has been shown recently that concurrent chemoradiotherapy gives a survival advantage in comparison with sequential chemoradiotherapy. - Cisplatin and etoposide are usually the drugs of choice for chemotherapy in patients with stage III cancer. - A biologically effective dose of radiotherapy equivalent to 60-66 Gy, over a maximum of 6.5 weeks, should be given. - Surgery is possible for a selected group of patients, provided a complete objective mediastinal response has been achieved after chemoradiotherapy and a complete resection appears to be technically feasible. It is recommended to apply this treatment in a research setting. - High-dose concurrent chemoradiotherapy is advised as the standard treatment for stage III non-small cell lung cancer in patients in good physical condition.
|Number of pages||4|
|Journal||Nederlands Tijdschrift voor Geneeskunde|
|Publication status||Published - 13 Dec 2008|